5 results match your criteria: "Cancer Institute of Hospices Civils de Lyon (IC-HCL)[Affiliation]"
Identification of Patients with Early HR+ HER2- Breast Cancer at High Risk of Recurrence.
Geburtshilfe Frauenheilkd
February 2024
University of Edinburgh Cancer Research Centre, Institute of Genetics and Cancer, Western General Hospital, Edinburgh, UK.
Article Synopsis
- Breast cancer rates have risen over the last 20 years, but survival has improved due to better detection and treatment, although some women still face relapses or metastases after initial treatment.
- About 70% of breast cancers are HR+ and HER2-, with a 20-year risk of recurrence, prompting a review of patient characteristics, biomarkers, and genomic tools for assessing high-risk cases.
- Accurate risk assessment is vital for treatment decisions, combining multiple prognostic tools and tailoring approaches to each patient’s situation to prevent over- or undertreatment.
Generation of Hybrid Extracellular Vesicles by Fusion with Functionalized Liposomes.
Methods Mol Biol
July 2022
Institut de Psychiatrie et Neurosciences de Paris, Inserm UMR 1266, Université de Paris, Paris, France.
Extracellular vesicles (EVs) and liposomes are natural and synthetic drug delivery systems, respectively, with their own advantages and limitations. EV/liposome fusion allows the generation of hybrid EVs that benefit from both the versatility of liposomes (tunable lipid and protein composition, surface functionalization, lumen loading, etc.) and the functionality of EVs (natural targeting properties, low immunogenicity, anti-inflammatory properties, etc.
View Article and Find Full Text PDFAutoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy.
Diabetes
January 2023
Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA.
Acquired lipodystrophy is often characterized as an idiopathic subtype of lipodystrophy. Despite suspicion of an immune-mediated pathology, biomarkers such as autoantibodies are generally lacking. Here, we used an unbiased proteome-wide screening approach to identify autoantibodies to the adipocyte-specific lipid droplet protein perilipin 1 (PLIN1) in a murine model of autoimmune polyendocrine syndrome type 1 (APS1).
View Article and Find Full Text PDFPARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers.
Cancers (Basel)
January 2022
Oncology Department, CITOHL, Lyon-Sud Hospital, Cancer Institute of Hospices Civils de Lyon (IC-HCL), Hospices Civils de Lyon, 69495 Lyon, France.
Recently, OlympiAD and EMBRACA trials demonstrated the favorable efficacy/toxicity ratio of PARPi, compared to chemotherapy, in patients with HER2-negative metastatic breast cancers (mBC) carrying a germline BRCA mutation. PARPi have been largely adopted in triple-negative metastatic breast cancer, but their place has been less clearly defined in endocrine-receptor positive, HER2 negative (ER+/ HER2-) mBC. The present narrative review aims at addressing this question by identifying the patients that are more likely benefit from PARPi.
View Article and Find Full Text PDFThe Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review.
Cancers (Basel)
December 2021
Oncology Department, CITOHL, Lyon-Sud Hospital, Cancer Institute of Hospices Civils de Lyon (IC-HCL), Hospices Civils de Lyon, 69495 Lyon, France.
Ovarian cancer is the gynecological cancer with the worst prognosis and the highest mortality rate because 75% of patients are diagnosed with advanced stage III-IV disease. About 50% of patients are now treated with neoadjuvant chemotherapy followed by interval debulking surgery (IDS). In that context, there is a need for accurate predictors of tumor primary chemosensitivity, as it may impact the feasibility of subsequent IDS.
View Article and Find Full Text PDF